[go: up one dir, main page]

MX2016016136A - Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. - Google Patents

Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.

Info

Publication number
MX2016016136A
MX2016016136A MX2016016136A MX2016016136A MX2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A MX 2016016136 A MX2016016136 A MX 2016016136A
Authority
MX
Mexico
Prior art keywords
increase
sleep
subject
reduce
methods
Prior art date
Application number
MX2016016136A
Other languages
English (en)
Other versions
MX380868B (es
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2016016136A publication Critical patent/MX2016016136A/es
Publication of MX380868B publication Critical patent/MX380868B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen métodos para incrementar la inhibición tónica en un sujeto en necesidad del mismo, por ejemplo, un sujeto con el síndrome Fragile X o el síndrome de Angelman. Los métodos para tratar insomnio secundario en un sujeto con un trastorno o desorden neurodegenerativo, también se describen. Los métodos pueden incluir administrar al sujeto una cantidad efectiva de 4,5,6,7-tetrahidroisoxazolo(5,4-c)piridina-3-ol (THIP) o un derivado de la misma, una sal farmacéuticamente aceptable de la misma, incrementar la inhibición tónica en neuronas del sujeto, para incrementar el sueño de onda lenta (SWS), y/o la actividad de onda lenta (SWA), normalizar la arquitectura del sueño, reducir el insomnio secundario, incrementar el sueño paradójico (NREM), incrementar la continuidad del sueño, mejorar la actividad delta dentro de NREM, incrementar o mejorar el tiempo total del sueño (TST), incrementar o mejorar la eficiencia del sueño, reducir el tiempo total despierto (TAA), reducir el número de despertamientos (NWA), reducir la latencia del sueño persistente (LPS) o reducir los despertamiento después de conciliar el sueño (WASO) en el sujeto, o cualquier combinación de los mismos.
MX2016016136A 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. MX380868B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (2)

Publication Number Publication Date
MX2016016136A true MX2016016136A (es) 2017-07-05
MX380868B MX380868B (es) 2025-03-12

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012404A MX391502B (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario
MX2016016136A MX380868B (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020012404A MX391502B (es) 2014-06-06 2015-06-03 Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario

Country Status (20)

Country Link
US (11) US20150352085A1 (es)
EP (3) EP3795156A1 (es)
JP (4) JP2017516868A (es)
AR (1) AR100772A1 (es)
AU (4) AU2015269667B2 (es)
CA (1) CA2950845C (es)
CY (2) CY1124366T1 (es)
DK (2) DK3372229T3 (es)
ES (2) ES2876350T3 (es)
HR (2) HRP20210901T1 (es)
HU (2) HUE055400T2 (es)
IL (2) IL249287B (es)
LT (2) LT3372229T (es)
MX (2) MX391502B (es)
PL (2) PL3372229T3 (es)
PT (2) PT3372229T (es)
RS (2) RS62007B1 (es)
SI (2) SI3151832T1 (es)
SM (2) SMT202100340T1 (es)
WO (1) WO2015187851A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100340T1 (it) 2014-06-06 2021-07-12 Ovid Therapeutics Inc Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
CA3113644A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
CN114786669A (zh) * 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
EP4153549A2 (en) 2020-05-20 2023-03-29 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20080269278A1 (en) 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
SMT202100340T1 (it) * 2014-06-06 2021-07-12 Ovid Therapeutics Inc Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
US20250025448A1 (en) 2025-01-23
HRP20210901T1 (hr) 2021-09-17
AU2020217342A1 (en) 2020-08-27
EP3372229B1 (en) 2021-03-24
US20160038469A1 (en) 2016-02-11
US20170071917A1 (en) 2017-03-16
LT3151832T (lt) 2021-07-12
AU2015269667B2 (en) 2020-07-30
MX380868B (es) 2025-03-12
LT3372229T (lt) 2021-07-12
IL249287B (en) 2021-03-25
EP3151832A4 (en) 2018-01-17
RS62007B1 (sr) 2021-07-30
US9339495B2 (en) 2016-05-17
AU2022200085A1 (en) 2022-02-03
JP2021178836A (ja) 2021-11-18
SI3372229T1 (sl) 2021-09-30
ES2875742T3 (es) 2021-11-11
US20160228418A1 (en) 2016-08-11
PL3151832T3 (pl) 2021-10-25
HUE055400T2 (hu) 2021-11-29
EP3151832B1 (en) 2021-03-24
US9744159B2 (en) 2017-08-29
AU2015269667A1 (en) 2016-12-22
US9446028B2 (en) 2016-09-20
SMT202100340T1 (it) 2021-07-12
JP2020063264A (ja) 2020-04-23
WO2015187851A1 (en) 2015-12-10
PL3372229T3 (pl) 2021-10-04
SMT202100343T1 (it) 2021-07-12
MX391502B (es) 2025-03-21
HUE055155T2 (hu) 2021-11-29
IL268960A (en) 2019-10-31
IL268960B (en) 2021-05-31
CA2950845A1 (en) 2015-12-10
US20170087133A1 (en) 2017-03-30
US11278529B2 (en) 2022-03-22
AU2024202604A1 (en) 2024-05-09
US20150352085A1 (en) 2015-12-10
US20220016091A1 (en) 2022-01-20
PT3372229T (pt) 2021-06-17
EP3795156A1 (en) 2021-03-24
JP2023123442A (ja) 2023-09-05
JP2017516868A (ja) 2017-06-22
DK3151832T3 (da) 2021-06-14
PT3151832T (pt) 2021-06-15
AR100772A1 (es) 2016-11-02
MX2020012404A (es) 2022-04-11
CA2950845C (en) 2023-04-25
EP3151832A1 (en) 2017-04-12
ES2876350T3 (es) 2021-11-12
EP3372229A1 (en) 2018-09-12
CY1124368T1 (el) 2022-07-22
US20180303805A1 (en) 2018-10-25
US20170273956A1 (en) 2017-09-28
IL249287A0 (en) 2017-02-28
AU2020217342B2 (en) 2021-10-07
RS62006B1 (sr) 2021-07-30
US9801864B2 (en) 2017-10-31
DK3372229T3 (da) 2021-06-14
US20230051859A1 (en) 2023-02-16
CY1124366T1 (el) 2022-07-22
US20180015076A1 (en) 2018-01-18
SI3151832T1 (sl) 2021-08-31
HRP20210902T1 (hr) 2021-09-17

Similar Documents

Publication Publication Date Title
MX2016016136A (es) Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
DOP2020000012A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
MX2024010140A (es) Nuevos metodos.
CY1121228T1 (el) 19-νορ c3,3-διϋποκατεστημενα c21-n-πypazoλyλ στεροειδη και μεθοδοι χρησης αυτων
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
CL2016000866A1 (es) Forma salina de hidrocloruro para la inhibición de ezh2
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20160205A (es) Inhibidores de kras g12c
CO2018013585A2 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para uso en el tratamiento de transtornos neurodegenerativos.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
MX2015011886A (es) Virus de la enfermedad de newcastle y usos de los mismos.
EA201792116A1 (ru) Ингибитор янус-киназы
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
UY37843A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
MX387969B (es) Composiciones y compuestos terapéuticos, y métodos para su uso.
UY36709A (es) Moduladores de ror gamma (ror¿)
MX2019014024A (es) Tratamiento de los trastornos depresivos.
NI201800071A (es) Compuestos de isoindol
MX2022000845A (es) Compuestos inhibidores.